BACKGROUND: While a close association between gastric mucosa associated lymphoid tissue (MALT) lymphoma and Helicobacter pylori infection has been established, there are still cases which do not respond to H pylori eradication. AIMS: To investigate the clinicopathological factors which may help predict the therapeutic efficacy of H pylori eradication in gastric MALT lymphoma. PATIENTS: Forty one patients with gastric MALT lymphoma, including low and high grade lesions. METHODS: After endosonographic staging was determined, H pylori was eradicated in all patients, and the subsequent gastric pathological course was then investigated. RESULTS: Complete regression of MALT lymphoma was observed in 29(71%) patients, partial regression in five (12%), and no regression in seven (17%). Twenty six (93%) of 28 MALT lymphomas restricted to the mucosa but only three (23%) of 13 lymphomas which invaded the deep portion of the submucosa or beyond completely regressed. Kaplan-Meier analysis for the probability of complete regression of MALT lymphoma revealed a significant difference between tumours restricted to the mucosa and those invading the submucosa deeply or beyond (p<0.05). Neither the presence of a high grade component, perigastric lymphadenopathy, nor clinical staging prior to eradication correlated with the probability of lymphoma regression. CONCLUSIONS: Assessment of deep submucosal invasion by endosonography is valuable for predicting the efficacy of H pylori eradication in gastric MALT lymphoma.
BACKGROUND: While a close association between gastric mucosa associated lymphoid tissue (MALT) lymphoma and Helicobacter pylori infection has been established, there are still cases which do not respond to H pylori eradication. AIMS: To investigate the clinicopathological factors which may help predict the therapeutic efficacy of H pylori eradication in gastric MALT lymphoma. PATIENTS: Forty one patients with gastric MALT lymphoma, including low and high grade lesions. METHODS: After endosonographic staging was determined, H pylori was eradicated in all patients, and the subsequent gastric pathological course was then investigated. RESULTS: Complete regression of MALT lymphoma was observed in 29(71%) patients, partial regression in five (12%), and no regression in seven (17%). Twenty six (93%) of 28 MALT lymphomas restricted to the mucosa but only three (23%) of 13 lymphomas which invaded the deep portion of the submucosa or beyond completely regressed. Kaplan-Meier analysis for the probability of complete regression of MALT lymphoma revealed a significant difference between tumours restricted to the mucosa and those invading the submucosa deeply or beyond (p<0.05). Neither the presence of a high grade component, perigastric lymphadenopathy, nor clinical staging prior to eradication correlated with the probability of lymphoma regression. CONCLUSIONS: Assessment of deep submucosal invasion by endosonography is valuable for predicting the efficacy of H pylori eradication in gastric MALT lymphoma.
Authors: M Sackmann; A Morgner; B Rudolph; A Neubauer; C Thiede; H Schulz; W Kraemer; G Boersch; P Rohde; E Seifert; M Stolte; E Bayerdoerffer Journal: Gastroenterology Date: 1997-10 Impact factor: 22.682
Authors: S Nakamura; K Aoyagi; M Furuse; H Suekane; T Matsumoto; T Yao; Y Sakai; T Fuchigami; I Yamamoto; M Tsuneyoshi; M Fujishima Journal: Am J Pathol Date: 1998-05 Impact factor: 4.307
Authors: M Lévy; P Hammel; D Lamarque; O Marty; M T Chaumette; C Haioun; M Blazquez; J C Delchier Journal: Gastrointest Endosc Date: 1997-10 Impact factor: 9.427
Authors: G Ott; T Katzenberger; A Greiner; J Kalla; A Rosenwald; U Heinrich; M M Ott; H K Müller-Hermelink Journal: Cancer Res Date: 1997-09-15 Impact factor: 12.701
Authors: A Neubauer; C Thiede; A Morgner; B Alpen; M Ritter; B Neubauer; T Wündisch; G Ehninger; M Stolte; E Bayerdörffer Journal: J Natl Cancer Inst Date: 1997-09-17 Impact factor: 13.506
Authors: C Thiede; A Morgner; B Alpen; T Wündisch; J Herrmann; M Ritter; G Ehninger; M Stolte; E Bayerdörffer; A Neubauer Journal: Gastroenterology Date: 1997-12 Impact factor: 22.682
Authors: J M Chong; M Fukayama; Y Hayashi; T Hishima; N Funata; M Koike; S Matsuya; M Konishi; M Miyaki Journal: Lab Invest Date: 1997-12 Impact factor: 5.662
Authors: H Ye; L Gong; H Liu; A Ruskone-Fourmestraux; D de Jong; S Pileri; C Thiede; A Lavergne; H Boot; G Caletti; T Wündisch; T Molina; B G Taal; S Elena; A Neubauer; K A Maclennan; R Siebert; E D Remstein; A Dogan; M-Q Du Journal: Gut Date: 2006-01 Impact factor: 23.059